R&D

Lilly finds solace in new Alzheimer's study

December 17, 2012
J.K. Wall
Eli Lilly and Co. suffered a delay in its effort to bring an Alzheimer’s drug to market this month, but it also published new research that the pharmaceutical company thinks confirms it is on the right track.
More

Lilly chief says China too slow in approving new drugs

November 28, 2012
Bloomberg News
China takes eight years longer on average to approve drugs than other major countries, and U.S. drugmakers are looking at ways to help speed things up, Eli Lilly and Co. CEO John Lechleiter said.
More

Drugmakers collaborate to facilitate drug tests

November 15, 2012
Associated Press
Eli Lilly and Co. and two other major drugmakers say they are collaborating in a global project aimed at getting patient tests of experimental drugs up and running more quickly and efficiently.
More

Lilly, Roche drugs chosen for Alzheimer’s prevention trial

October 10, 2012
Bloomberg News
Eli Lilly & Co.’s solanezumab and Roche Holding AG’s gantenerumab were selected for a long-term Alzheimer’s trial run by Washington University at St. Louis scientists seeking to block the disease’s symptoms.
More

Group aims to cut costs of late-stage drugs

September 24, 2012
J.K. Wall
You know things are bad in the fiercely competitive pharma industry when drugmakers start turning to each other for help. But that’s exactly what happened last week when 10 major drug companies—including Eli Lilly and Co.—joined forces to cut costs out of clinical trials.
More

Lilly stops testing of experimental schizophrenia drug

August 29, 2012
Bloomberg News
Eli Lilly and Co. halted testing on an experimental treatment for schizophrenia after the company determined the drug was unlikely to show a benefit in patients.
More

Alzheimer's quest puts Lilly to test

August 11, 2012
J.K. Wall
Odds are long that Eli Lilly and Co.'s leading Alzheimer's drug will show positive results when its Phase 3 trial results are released within a few weeks, but even the smallest improvement in the cognitive impairment of test patients would be a home run for Lilly.
More

Potential Lilly antipsychotic falls short in study

July 11, 2012
Associated Press
Eli Lilly and Co. said a potential treatment for acute schizophrenia failed in a late-stage study that compared patients taking the drug to those taking a placebo.
More

Good cholesterol may not lower heart risk, study suggests

May 17, 2012
Bloomberg News
Raising good cholesterol, a goal pursued by Eli Lilly and Co. as the next milestone in cardiac care, may not cut heart-attack risk, says a study that challenges the development of drugs that may someday generate billions of dollars in sales.
More

Roche scraps hoped-for cholesterol blockbuster

May 7, 2012
Associated Press
A second experimental cholesterol medicine in a once-promising class of drugs meant to replace blockbusters such as Lipitor has failed in testing, casting doubt on whether any of the drugs will ever make it to pharmacies. Eli Lilly is developing a similar drug.
More

Lilly letting U.S. researchers test failed compounds for new uses

May 3, 2012
Bloomberg News
More than 20 compounds that Eli Lilly and Co., Pfizer Inc. and AstraZeneca Plc failed to turn into drugs will be tested by U.S.-sponsored scientists in a $20 million program to see if they’ll work against ailments they weren’t aimed at previously.
More

Endocyte could get $1B from Merck development deal

April 16, 2012
Associated Press
Endocyte Inc. stock more than doubled in premarket trading after the company entered into an agreement to develop its ovarian cancer treatment with pharmaceutical giant Merck & Co.
More

Endocyte pulls trigger on European drug submission

March 13, 2012
J.K. Wall
Endocyte Inc. will submit its ovarian cancer drug EC145 for European market approval in the third quarter of this year after the European Commission granted it orphan drug status.
More

FDA removes hurdle in Endocyte's path to drug approval

March 5, 2012
J.K. Wall
Endocyte Inc. can start enrolling patients again in a clinical trial of its experimental cancer drug, the company announced Monday, clearing away a hurdle to getting the drug approved in Europe.
More

Lechleiter bets history will repeat for Lilly

January 16, 2012
J.K. Wall
Eli Lilly and Co. CEO John Lechleiter keeps pouring more money into research and development, even as analysts note the payoff of such spending has dropped off 70 percent in the last decade.
More

Pressure rises as Lilly tries squeeze play

January 9, 2012
J.K. Wall
Indianapolis-based Eli Lilly and Co. is now in the predicament of watching revenue fall as its patents on older products expire, even as the company needs to spend more money on marketing and research to boost sales of new drugs.
More

Lilly losing dominance in diabetes treatmentRestricted Content

December 31, 2011
J.K. Wall
Eli Lilly and Co., after more than a decade of setbacks, is counting on diabetes to help it survive a string of patent losses on other products that have begun to sap the drugmaker's sales.
More

Endocyte shares plunge on clinical trial results

December 13, 2011
J.K. Wall
Shares of Endocyte Inc. plummeted more than 60 percent Tuesday morning after clinical trial results showed the company’s experimental ovarian cancer drug led to shorter survival times than treatment with a standard cancer drug.
More

Potential Lilly drug doubles good cholesterol

November 15, 2011
Bloomberg News
Eli Lilly and Co.’s experimental drug doubled levels of good cholesterol in a study, setting up a race with Merck & Co. and Roche Holding AG to develop a new class of medicines to lower heart risk.
More

Cash-strapped Arcadia seeks DailyMed buyer

November 15, 2011
Scott Olson
The Indianapolis-based company is searching for a buyer for its once-promising DailyMed pharmacy service as it struggles to pay $30 million in debt that comes due in April.
More

Potential Effient rival shows promise in study

November 14, 2011
Bloomberg News
A study showing Johnson & Johnson and Bayer AG’s blood-thinner Xarelto succeeded where rival drugs failed could give the companies entry to a $1 billion-plus market where Eli Lilly already competes.
More

Drug shortages hit Lilly, Endocyte

November 7, 2011
J.K. Wall
The nation’s shortage of certain drugs is threatening to affect research trials being conducted by Eli Lilly and Co. and Endocyte Inc.
More

Q&A

October 17, 2011
J.K. Wall
Sherry Keramidas, who earned her doctorate in neuroscience and physiological psychology from Purdue University, is executive director of the Maryland-based Regulatory Affairs Professionals Society, which is holding its annual conference Oct. 22-26 at the Indiana Convention Center.
More

Lilly's Alimta get favorable opinion for new use in Europe

September 26, 2011
J.K. Wall
If approved for continuation maintenance, Eli Lilly and Co.'s Alimta could be used for longer stretches in lung cancer patients, generating more revenue.
More

Lilly: Alzheimer's patients on failed drug didn’t improve

July 19, 2011
Bloomberg News
Eli Lilly and Co. said patients with Alzheimer’s disease whose conditions worsened upon taking the experimental drug semagacestat didn’t improve after dosing was halted.
More
Page  << 1 2 3 4 5 6 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Apologies for the wall of text. I promise I had this nicely formatted in paragraphs in Notepad before pasting here.

  2. I believe that is incorrect Sir, the people's tax-dollars are NOT paying for the companies investment. Without the tax-break the company would be paying an ADDITIONAL $11.1 million in taxes ON TOP of their $22.5 Million investment (Building + IT), for a total of $33.6M or a 50% tax rate. Also, the article does not specify what the total taxes were BEFORE the break. Usually such a corporate tax-break is a 'discount' not a 100% wavier of tax obligations. For sake of example lets say the original taxes added up to $30M over 10 years. $12.5M, New Building $10.0M, IT infrastructure $30.0M, Total Taxes (Example Number) == $52.5M ININ's Cost - $1.8M /10 years, Tax Break (Building) - $0.75M /10 years, Tax Break (IT Infrastructure) - $8.6M /2 years, Tax Breaks (against Hiring Commitment: 430 new jobs /2 years) == 11.5M Possible tax breaks. ININ TOTAL COST: $41M Even if you assume a 100% break, change the '30.0M' to '11.5M' and you can see the Company will be paying a minimum of $22.5, out-of-pocket for their capital-investment - NOT the tax-payers. Also note, much of this money is being spent locally in Indiana and it is creating 430 jobs in your city. I admit I'm a little unclear which tax-breaks are allocated to exactly which expenses. Clearly this is all oversimplified but I think we have both made our points! :) Sorry for the long post.

  3. Clearly, there is a lack of a basic understanding of economics. It is not up to the company to decide what to pay its workers. If companies were able to decide how much to pay their workers then why wouldn't they pay everyone minimum wage? Why choose to pay $10 or $14 when they could pay $7? The answer is that companies DO NOT decide how much to pay workers. It is the market that dictates what a worker is worth and how much they should get paid. If Lowe's chooses to pay a call center worker $7 an hour it will not be able to hire anyone for the job, because all those people will work for someone else paying the market rate of $10-$14 an hour. This forces Lowes to pay its workers that much. Not because it wants to pay them that much out of the goodness of their heart, but because it has to pay them that much in order to stay competitive and attract good workers.

  4. GOOD DAY to you I am Mr Howell Henry, a Reputable, Legitimate & an accredited money Lender. I loan money out to individuals in need of financial assistance. Do you have a bad credit or are you in need of money to pay bills? i want to use this medium to inform you that i render reliable beneficiary assistance as I'll be glad to offer you a loan at 2% interest rate to reliable individuals. Services Rendered include: *Refinance *Home Improvement *Inventor Loans *Auto Loans *Debt Consolidation *Horse Loans *Line of Credit *Second Mortgage *Business Loans *Personal Loans *International Loans. Please write back if interested. Upon Response, you'll be mailed a Loan application form to fill. (No social security and no credit check, 100% Guaranteed!) I Look forward permitting me to be of service to you. You can contact me via e-mail howellhenryloanfirm@gmail.com Yours Sincerely MR Howell Henry(MD)

  5. It is sad to see these races not have a full attendance. The Indy Car races are so much more exciting than Nascar. It seems to me the commenters here are still a little upset with Tony George from a move he made 20 years ago. It was his decision to make, not yours. He lost his position over it. But I believe the problem in all pro sports is the escalating price of admission. In todays economy, people have to pay much more for food and gas. The average fan cannot attend many events anymore. It's gotten priced out of most peoples budgets.

ADVERTISEMENT